

1
2
3
4
5 IN THE UNITED STATES DISTRICT COURT
6 FOR THE NORTHERN DISTRICT OF CALIFORNIA
7

8 ROBERT E. FIGY, individually and on behalf of
9 all others similarly situated,

No. C 13-03816-SI

10 Plaintiff,

v.

**ORDER GRANTING DEFENDANT'S
MOTION TO DISMISS PLAINTIFF'S
FIRST AMENDED CLASS ACTION
COMPLAINT**

11 AMY'S KITCHEN, INC.,

12 Defendant.
13 _____/

14 Now before the Court is a motion by defendant Amy's Kitchen, Inc. ("Amy's Kitchen") to
15 dismiss plaintiff's first amended class action complaint. Docket No. 48. The motion is scheduled for
16 a hearing on April 25, 2014. Pursuant to Civil Local Rule 7-1(b), the Court finds this matter appropriate
17 for resolution without oral argument, and hereby VACATES the hearing. For the reasons set forth
18 below, the Court GRANTS defendant's motion to dismiss and DISMISSES the action WITHOUT
19 PREJUDICE pursuant to the doctrine of primary jurisdiction.
20

21 **BACKGROUND**

22 This is a consumer class action. Defendant Amy's Kitchen markets and sells a number of
23 products listing "evaporated cane juice" or "organic evaporated cane juice" ("ECJ") as an ingredient
24 on the product's labeling. Docket No. 44, First Amended Complaint ("FAC") ¶¶ 2, 5 (Table 1).
25 Plaintiff alleges that using the term ECJ violates Food and Drug Administration ("FDA") regulations
26 which require food labels to reflect the common or usual name of an ingredient. FAC ¶¶ 5, 24, 44, 48
27 (citing 21 C.F.R. §§ 101.3, 101.4, 102.5, 131.200, 184.1854, 1.21, 120.1, 168.130.). Plaintiff alleges
28 that the common or usual name for ECJ is actually "sugar," and that defendant uses the term ECJ instead

1 of the term “sugar” to make its products appear healthier to consumers. FAC ¶¶ 17, 41. Plaintiff further
 2 alleges that defendant’s failure to comply with these FDA regulations violates California’s Sherman
 3 Law (“Sherman Law”), California Health and Safety Code § 109875 et seq. *Id.* ¶¶ 8-10, 37-38, 61-65.

4 Based upon those alleged violations, plaintiff filed a class action complaint against Amy’s
 5 Kitchen on August 16, 2013. Docket No. 1, Compl. On November 25, 2013, the Court granted
 6 defendant’s motion to dismiss the complaint with leave to amend. Docket No. 38. On December 13,
 7 2013, plaintiff filed the FAC, asserting causes of action under the following California consumer
 8 protection statutes: (1) the Unfair Competition Law (“UCL”) for unlawful business practices; (2) the
 9 UCL for unfair business practices; (3) the UCL for fraudulent business practices; (4) the False
 10 Advertising Law (“FAL”) for misleading and deceptive advertising; (5) the FAL for untrue advertising;
 11 and (6) the Consumer Legal Remedies Act (“CLRA”) for unlawful sale of misbranded products and
 12 misrepresentations regarding those products. *See* FAC. Plaintiff also alleges causes of action for: (7)
 13 breach of express warranty; (8) breach of implied warranty; (9) negligent misrepresentation; (10)
 14 negligence; (11) unjust enrichment; (12) recovery in assumpsit; and (13) declaratory relief. *Id.* By the
 15 present motion, defendant moves to dismiss plaintiff’s FAC. Docket No. 48, Motion to Dismiss.

17 DISCUSSION

18 Among other grounds, Amy’s Kitchen moves to dismiss the FAC based upon the doctrine of
 19 primary jurisdiction. Amy’s Kitchen argues that, because food labeling is within the special competence
 20 of the FDA, and the FDA has not finalized its position on the term ECJ, the Court should apply the
 21 doctrine of primary jurisdiction, defer to the agency, and dismiss the action without prejudice. Docket
 22 No. 48, Motion to Dismiss at 13-19. In response, plaintiff contends that the doctrine of primary
 23 jurisdiction does not apply in these circumstances because the FDA has “unwaveringly maintained since
 24 at least 2000 that the use of ECJ on food ingredient lists is illegal.” Docket No. 50, Pl’s Opp. at 11.

26 I. Legal Standard

27 “The primary jurisdiction doctrine allows courts to stay proceedings or to dismiss a complaint
 28 without prejudice pending the resolution of an issue within the special competence of an administrative

agency.” *Clark v. Time Warner Cable*, 523 F.3d 1110, 1114 (9th Cir. 2008). “[T]he doctrine is a ‘prudential’ one, under which a court determines that an otherwise cognizable claim implicates technical and policy questions that should be addressed in the first instance by the agency with regulatory authority over the relevant industry rather than by the judicial branch.” *Id.* Although no fixed formula exists for applying the doctrine, the Ninth Circuit has traditionally examined the following factors: “(1) [a] need to resolve an issue that (2) has been placed by Congress within the jurisdiction of an administrative body having regulatory authority (3) pursuant to a statute that subjects an industry or activity to a comprehensive regulatory authority that (4) requires expertise or uniformity in administration.” *Clark*, 523 F.3d at 1115; *see also Chabner v. United of Omaha Life Ins. Co.*, 225 F.3d 1042, 1051 (9th Cir. 2000) (in determining whether to apply the doctrine of primary jurisdiction, a court should consider “(1) whether application will enhance court decision-making and efficiency by allowing the court to take advantage of administrative expertise; and 2) whether application will help assure uniform application of regulatory laws.”).

Primary jurisdiction may be invoked when an agency is addressing an issue through formal rulemaking procedures, as well as through adjudicative procedures. *See, e.g., Clark*, 523 F.3d at 1114-16; *Kappelmann v. Delta Air Lines, Inc.*, 539 F.2d 165, 169 (D.C. Cir. 1976). Several courts within this district have found application of the primary jurisdiction doctrine appropriate “where a determination of a plaintiff’s claim would require a court to decide an issue committed to the FDA’s expertise without a clear indication of how the FDA would view the issue.” *Hood v. Wholesoy & Co, Modesto Wholesoy Co. LLC*, 12-CV-5550-YGR, 2013 WL 3553979, at *5 (N.D. Cal. Jul. 12, 2013); *see also, e.g., Reese v. Odwalla, Inc.*, 13-CV-00947-YGR, 2014 U.S. Dist. LEXIS 40341, at *8 (N.D. Cal. Mar. 25, 2014); *Ivie v. Kraft Foods Global, Inc.*, C-12-02554-RMW, 2013 WL 685372, at *7 (N.D. Cal. Feb. 25, 2013); *Astiana v. Hain Celestial*, 905 F. Supp. 2d 1013, 1016-17 (N.D. Cal. 2012); *Gordon v. Church & Dwight Co.*, C 09-5585 PJH, 2010 WL 1341184, at *2 (N.D. Cal. Apr. 2, 2010).

II. Analysis

Food labeling is within the special competence of the FDA. *Morgan v. Wallaby Yogurt Co., Inc.*, 13-CV-00296-WHO, 2013 WL 5514563, at *4 (N.D. Cal. Oct. 4, 2013); *Hood*, 2013 WL 3553979, at

1 *16. “The issue of proper declaration of ingredients on food labels is one as to which Congress vested
 2 the FDA with comprehensive regulatory authority.” *Reese*, 2014 U.S. Dist. LEXIS 40341, at *12 (citing
 3 21 U.S.C. § 301 *et seq* and 21 U.S.C. § 341 *et seq*); *accord Astiana*, 905 F. Supp. 2d at 1015 (“[I]ssues
 4 of beverage labeling have been entrusted by Congress to the FDA, pursuant to the FDCA (and its related
 5 regulations) . . .”).

6 Specific to the present case, FDA regulations require that manufacturers list ingredients “on the
 7 label or labeling of a food . . . by [their] common or usual name.” 21 C.F.R. § 101.4(a)(1). The
 8 regulations provide that the “common or usual name of a food may be established by common usage or
 9 by establishment of a regulation.” 21 C.F.R. § 102.5(d). All of the claims in the FAC hinge on plaintiff’s
 10 contention that ECJ is not the common or usual name of the ingredient at issue, thereby rendering
 11 defendant’s products in violation of the above federal regulations and illegal under California’s Sherman
 12 Law. *See generally* FAC. Therefore, the issues raised by plaintiff’s complaint “fit[] squarely within”
 13 Congress’ delegation of authority to the FDA. *Clark*, 523 F.3d at 1115.

14 The parties dispute whether the FDA has resolved the issue of whether ECJ is the common or
 15 usual name of the ingredient at issue.

16 Plaintiff argues that the FDA has consistently maintained since at least 2000 that the use of ECJ
 17 on food ingredient lists is false and misleading because ECJ is not the common or usual name for that
 18 ingredient. Docket No. 50, Pl’s Opp. at 11; *see also* FAC ¶¶ 45-53. In support of his contention, plaintiff
 19 relies on a 2009 draft guidance issued by the FDA and several warning letters. *See id.* In the 2009 draft
 20 guidance, the FDA states that it is advising the regulated industry that the FDA’s view is that “evaporated
 21 cane juice” is not the common or usual name of any type of sweetener. Docket No. 26-1, Request for
 22 Judicial Notice Ex. A.

23 However, the 2009 draft guidance further states: “This guidance is being distributed for comment
 24 purposed only” and “Draft - Not for Implementation.” *Id.* at 1. In addition, the guidance explains that
 25 it will only represent the FDA’s current thinking on the topic once the guidance is finalized. *Id.*
 26 Therefore, it is apparent from the face of the 2009 Draft Guidance that it only represents the FDA’s
 27 preliminary view of the issue and not its formal position.

28 Moreover, on March 5, 2014, the FDA issued a notice in the Federal Register reopening the

comment period for the draft guidance on the use of the term ECJ.¹ Docket No. 52-1, Request for Judicial Notice Ex. A. The notice confirms that the 2009 draft guidance merely represents the FDA’s “preliminary thinking regarding the use of the term” ECJ, and the FDA has “not reached a final decision on the common or usual name of the ingredient.” *Id.* The notice explains that the FDA is seeking additional information on ECJ’s method of production, the differences between ECJ and other sweeteners, and its basic characterizing properties. *Id.* The notice also states that after reviewing the comments the FDA intends to revise the draft guidance, if appropriate, and issue it in final form. *Id.* The relevant federal regulations explain that “[g]uidance documents are documents prepared for FDA staff, applicants/sponsors, and the public that describe the agency’s interpretation of or policy on a regulatory issue.” 21 C.F.R. § 10.115(b)(1).

In light of the March 5, 2014 notice, the Court finds it appropriate to apply the doctrine of primary jurisdiction. The notice states that the FDA has not resolved the issue of whether ECJ is the common or usual name of the ingredient at issue and that the FDA is engaged in active rulemaking on the issue. Further, the determination of whether ECJ is the common or usual name of the ingredient is best left to the FDA for resolution. As the March 5, 2014 notice states, consideration of whether ECJ is the common or usual name of the ingredient involves consideration of ECJ’s method of production, the differences between ECJ and other sweeteners, and its basic characterizing properties. Resolution of these issues requires the expertise of the FDA. *See also United States v. W. Pac. R. Co.*, 352 U.S. 59, 64 (1956) (“[I]n cases raising issues of fact not within the conventional experience of judges or cases requiring the exercise of administrative discretion, agencies created by Congress for regulating the subject matter should not be passed over.”). Deferring to the FDA for resolution of these issues “will enhance decision-making and efficiency by allowing the court to take advantage of administrative expertise.” *See Chabner*, 225 F.3d at 1051.

Moreover, deferring to the FDA will allow for uniformity in administration on this issue. If the

¹ The March 5, 2014 notice was first raised by defendant in its reply brief dated March 7, 2014. Docket No. 51, Def.’s Reply at 4. Generally, it is improper to raise new issues in a reply brief. *See Cedano-Viera v. Ashcroft*, 324 F.3d 1062, 1066 n.5 (9th Cir. 2003). However, the Court concludes that it is appropriate to do so here because the notice did not exist when defendant filed its motion to dismiss on January 29, 2014, and plaintiff was given leave to and did file a supplemental brief on the issue. *See* Docket No. 58, Supplemental Brief.

1 Court were to proceed with this action and issue a decision that is contrary to the FDA's formal position
 2 on ECJ, it would disrupt the uniform application of the FDA's regulatory rules. *See United States v.*
 3 *Philip Morris USA Inc.*, 686 F.3d 832, 837 (D.C. Cir. 2012) ("The primary jurisdiction doctrine rests
 4 . . . on a concern for uniform outcomes (which may be defeated if disparate courts resolve regulatory
 5 issues inconsistently) . . ."). For this reason, courts find it particularly appropriate to defer to an agency
 6 when, as is true here, the agency is in the process of making a determination on a key issue in the
 7 litigation. *See Clark*, 523 F.3d at 1115 (explaining that application of the primary jurisdiction doctrine
 8 was appropriate because the "agency is actively considering how it will regulate VoIP services and [] the
 9 agency's development of a uniform regulatory framework to confront this emerging technology is
 10 important to federal telecommunications policy"); *Gordon*, 2010 WL 1341184, at *2 (applying primary
 11 jurisdiction; "[because] this issue remains under review," "[i]t would be inappropriate for this court to
 12 assume the FDA's regulatory role").

13 In sum, applying the doctrine of primary jurisdiction allows the Court to benefit from the FDA's
 14 expertise on food labeling and will ensure uniformity in administration of the regulations.² *See Reese*,
 15 2014 U.S. Dist. LEXIS 40341, at *16 ("In light of the fact that FDA has revived its review of the ECJ
 16 issue, the Court finds that the FDA's position on the lawfulness of the use of that term is not only . . . 'not
 17 settled,' it is also under active consideration by the FDA. Any final pronouncement by the FDA in

18
 19 ² Plaintiff argues that the doctrine of primary jurisdiction is inapplicable where the agency cannot
 20 award a plaintiff the same relief as a court, Docket No. 58, Supplemental Brief at 6, citing *Rosado v.*
 21 *Wyman*, 397 U.S. 397, 406 (1970). However, the Supreme Court in *Rosado* merely held that the
 22 doctrine of primary jurisdiction is inapplicable where the agency does not allow plaintiffs to "initiate
 or participate" in the administrative proceedings. *Id.* Here, the FDA has already initiated rulemaking
 procedures on the issue, and plaintiff concedes that he is allowed to participate in the proceedings by
 submitting comments. Supplemental Brief at 6. Therefore, *Rosado* is inapplicable to the present
 circumstances.

23 Plaintiff also cites to *Rhoades v. Avon Products, Inc.*, 504 F.3d 1151 (9th Cir. 2007), but this
 24 case is distinguishable. In *Rhodes*, the Ninth Circuit declined to apply primary jurisdiction because of
 25 the unique nature of the relevant agency. The court explained that unlike other agencies, the Patent and
 26 Trademark Organization ("PTO") has not been designated by Congress as the exclusive expert in the
 27 field. *Id.* at 1164 ("Allowing the district court to decline a declaratory relief action on a primary
 28 jurisdiction rationale is sensible only if the agency is better equipped to handle the action. Here,
 however, Congress has not installed the PTO as the exclusive expert in the field."). Additionally, the
 Ninth Circuit explained that "federal courts are particularly well-suited to handle the claims" at issue
 in that plaintiff's action. *Id.* In contrast, here the issue of the proper labeling of food ingredients is one
 as to which Congress has vested the FDA with comprehensive regulatory authority. *See Reese*, 2014
 U.S. Dist. LEXIS 40341, at *12 (citing 21 U.S.C. § 301 *et seq* and 21 U.S.C. § 341 *et seq*). Moreover,
 the present case requires the determination of issues that require the expertise of the FDA. *See id.* at
 *14; *Hood*, 2013 WL 3553979, at *5.

connection with that process almost certainly would have an effect on the issues in litigation here.”). All of plaintiff’s claims hinge on his contention that ECJ is not the common and usual name for the ingredient found in defendant’s products.³ Therefore, the Court finds it appropriate to dismiss the action without prejudice pursuant to the doctrine of primary jurisdiction.⁴ See, e.g., *Hood*, 2013 WL 3553979, at *6 (dismissing without prejudice, among others, plaintiff’s UCL, FAL, CLRA, and contract claims under the doctrine of primary jurisdiction); *Astiana*, 905 F. Supp. 2d at 1017 (dismissing without prejudice plaintiff’s UCL, FAL, CLRA, and fraud claims under the doctrine of primary jurisdiction).

CONCLUSION

Accordingly, the Court GRANTS defendant’s motion to dismiss and DISMISSES the action WITHOUT PREJUDICE, pursuant to the doctrine of primary jurisdiction. Docket No. 48.

IT IS SO ORDERED.

Dated: April 9, 2014



SUSAN ILLSTON
UNITED STATES DISTRICT JUDGE

³ Plaintiff argues that his lawsuit will not be affected if the FDA does revise its guidance, because defendant will continue to be bound by the existing “sugar” statutes and regulations that require that the ingredient at issue be called “sugar.” Docket No. 58, Supplemental Brief at 5 (citing 21 C.F.R. §§ 101.4(a)(1), 101.4(b)(20), 102.5(d), 184.1854). However, elsewhere in the brief, plaintiff concedes that “[t]he FDA . . . does permit certain sweeteners derived from sugar cane to be referred to by slightly different names.” *Id.* at 4. Therefore, it is possible that future FDA action could find that the term ECJ is the common and usual name of that ingredient and is in compliance with the relevant statutes and regulations governing “sugar.”

⁴ In his supplemental brief, plaintiff cites to the recent decision in *Swearingen v. Amazon Preservation Partners, Inc.*, 13-CV-04402-WHO, 2014 U.S. Dist. LEXIS 36830 (N.D. Cal. Mar. 18, 2014). Docket No. 58, Supplemental Brief at 3. In *Swearingen/Amazon*, the district court declined to apply the doctrine of primary jurisdiction, notwithstanding the FDA’s issuance of the March 5, 2014 notice, because “it remains unclear when or if the FDA will conclusively resolve the issue.” *Id.* at *11 n.3. However, the March 5, 2014 notice explicitly states that after reviewing comments, the FDA intends to issue guidance in final form. Docket No. 32, Ex. 1. Therefore, the Court declines to follow *Swearingen/Amazon*. See also *Reese*, 2014 U.S. Dist. LEXIS 40341 at *10, 16 (applying the doctrine of primary jurisdiction based on the March 5, 2014 notice in part because the FDA stated it will issue final guidance on the use of the term ECJ).